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Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disorder, which 
is now ranked equal third as a leading cause of death [1]. Fixed airflow obstruction that is 
measured by spirometry following inhaled bronchodilator is essential to its diagnosis, and in its 
advanced stages, systemic manifestations such as inflammation and cachexia are also 
characteristic.  In the lung, pathological features include increased numbers of airway neutrophils, 
a cytotoxic (Tc) predominant lymphocytic response associated with lymphoid follicles containing B 
and T cells, and proinflammatory cytokines including interleukin (IL)-6 and IL-8. Lung fibrosis and 
parenchymal destruction, otherwise known as emphysema can also feature in addition to small 
airways obstruction, and some evidence suggest these processes are linked to the proteolytic 
enzymes, matrix metalloproteinases (MMP).   
  
While the predominant immune response in allergic asthma resembles the TH2 pattern, a TH1 
lymphocytic response appears to predominate in COPD.  Interferon gamma (IFN-γ) attracts TH1 
and Tc1 cells into the lung and this results in persistent inflammatory activation, with possible Tc1-
related lung damage via type 1 pneumocyte apoptosis [2].  However, the distinction between 
asthma and COPD in terms of inflammatory and immune responses is often not clear [2].  In a 
study that examined bronchoalveolar lavage (BAL) specimens from COPD patients, IL-4 and IL-13 
expression were increased largely by pulmonary Tc2 lymphocytes, and levels were inversely 
correlated with the degree of fixed airflow obstruction or COPD severity [3]. Up to 40% of patients 
with stable COPD have been shown to exhibit sputum eosinophilia [4, 5] that is most apparent 
during acute COPD exacerbations, thus resembling the immunological profile which is typical of 
acute asthma exacerbations.  This may be primarily mediated by the cytokines IL-5, eotaxin and 
RANTES [6], via increased eosinophil production and release from bone marrow [5]. 
  
Systemic inflammation in COPD has been best demonstrated by the presence of raised high-
sensitive C-reactive protein levels, which have been shown to correlate with disease severity, but 
not with prognosis or accelerated lung function decline. Increasing COPD severity has been 
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associated with increasing plasma concentrations of IL-13, CCL2 (MCP-1), CCL4 (MIP-1β), CCL11 
(eotaxin) but not with IL-1β in stable COPD subjects.  In a study that measured multiple serum 
cytokines in 21 stable COPD patients, serum CCL11 (eotaxin) and IL-6 were elevated compared 
with controls. This contrasted cytokines from the TH2 and TH17 lineage which did not show 
significant differences. 
   
A distinct CD4+ T-cell subset, TH17 cells, produce IL-17A that regulates neutrophil emigration and 
systemic granulopoietic responses to both pulmonary bacterial and allergen challenges.  While this 
TH17 pathway is  involved in host defence against extracellular bacteria and autoimmune disease  
and has been linked to allergic asthma, bacterial pneumonia and acute rejection in lung 
transplantation, its involvement in COPD is unclear.   
  
COPD-related inflammation continues to progress, even despite the cessation of smoking. It is 
unclear if this is due to persistent microbial colonisation, to persistent toxic stimuli in a susceptible 
individual, or possibly due to autoantigens that develop in repetitively damaged tissue.  In this 
context, we aimed to measure serum cytokine levels representative of the TH1, TH2 and TH17 
inflammatory pathways by multiplex immunobead-based assay in those with severe COPD, mild-
moderate COPD and those without COPD. 
 
Here, we studied participants with and without physician-diagnosed COPD who were either ex-
smokers or current smokers with at least a 10 pack-year history of smoking. Non-smokers with 
fixed airflow obstruction and emphysema documented by high-resolution computerised tomography 
chest scanning were also included in the study as comparison.  Fixed airflow obstruction was 
defined as a ratio of post-bronchodilator forced expiratory volume in one second/ forced vital 
capacity (FEV1/FVC) below the lower limit of the predicted normal range.  As per the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy Document, severe COPD was 
defined as a FEV1 less than 50% predicted, and mild-moderate COPD was defined by a FEV1 
greater than or equal to 50% predicted in this study.  Control participants included those that were 
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match as much as possible, being either current smokers, ex-smokers or non-smokers with a ratio 
of FEV1/FVC within the normal predicted range. Exclusion criteria included a self-reported or 
physician-diagnosis of asthma, a respiratory infection within the preceding 4 weeks, current use of 
oral corticosteroids, known bronchiectasis or alternative systemic inflammatory disorder, and 
significant co-morbidity. The study protocol was approved by Austin Health Human Research 
Ethics Committee, and all participants provided written, informed consent.  Venous blood was 
collected, serum isolated and tested using bead-based multiplex immunoassay for cytokines (MIA, 
9 Bio-Plex Panel B, BioRad Laboratories Inc.) - IL-12p70, IL-5, IL-13, IL-17A, IL-7, G-CSF, IL-1β, 
CCL2 and CCL4.  Thawed serum samples were diluted in a ratio of 1:3 with the human serum 
specific diluent.  High PMT standard settings were prepared with “blank” negative controls in 
duplicate. Ninety-six-well plates were coated with beads, followed by the addition of samples and 
standards and detection antibodies, then streptavidin-phytoerythrin as per manufacturer’s 
instructions. The beads were resuspended and then the fluorescence output was read and 
calculated on the Bio-Plex array reader; all relevant controls were included to validate the cytokine 
analyis. Non-parametric analysis of variance (Kruskal-Wallis test) was used to compare the means 
between the three groups.  Spearman rank correlations were used to compare values between 
individual cytokines. A conventional cut-off of p < 0.05 was used to determine statistical 
significance. 
 
The demographic and lung function data of the 35 participants are summarised in Table 1.  There 
was a male predominance in the combined COPD group (n = 13, 68%), and a female 
predominance in the control group (n = 11, 69%).  Those with COPD were on average between 11 
and 12 years older than the control participants (p = 0.01).  Significant differences in lung function 
were seen between participant groups, where the mean FEV1 was 37% of predicted for those with 
severe COPD, 70% of predicted for those with mild-to-moderate COPD and 109% of predicted for 
control subjects.  Gas transfer factor measurements were significantly lower for COPD patients 
with severe airflow obstruction, when compared with those who had mild-to-moderate disease 
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[40.4% of predicted (95% confidence interval (CI) 26-54) versus 55.8% of predicted (95%CI 43-
69)]. 
 
Individual levels of each cytokine are illustrated in Figure 1a, where there were no differences 
between control and COPD groups, and between COPD severity categories, for most of the 
cytokines tested. A significant difference in serum IL-5 levels was noted between those who had 
severe COPD to those who had mild-to-moderate COPD or controls (Figure 1a, p = 0.005).  
Although most participants had undetectable levels of IL-5, half the individuals in the severe COPD 
group (n = 4) had detectable levels with a mean (SEM) level of 6.4 (3.2) pg/ml.  Similarly, half with 
severe COPD had detectable IL-13 levels, although the trend in levels between groups did not 
quite reach statistical significance (p = 0.079) (Figure 1a).  A modest correlation was noted 
between the TH2 type cytokines, IL-5 and IL-13 (Spearman r = 0.429, p = 0.0102). However, 
moderate correlations were noted between lineages, namely IL-17A and IL-12p70 (Spearman r = 
0.52, p = 0.0015), as well as between IL-17A and IL-13 (Spearman r = 0.55, p = 0.0006) (Figure 
1b, 1c).  
 
This study has documented levels of serum cytokine that are representative of the TH1, TH2 and 
TH17 pathways in COPD patients with mild-to-moderate and severe airflow obstruction.  Although a 
T-lymphocyte type 1 response that primarily involves IFN-γ predominates in COPD [2], our 
detection of serum IL-5 levels in those with severe COPD and a lower gas transfer factor supports 
the body of evidence that suggests type 2 responses co-exist, especially during exacerbations.  
Oral corticosteroid therapy has been shown to reduce sputum eosinophilic cationic protein and 
blood eosinophil count in patients with stable COPD in whom asthma was excluded, and an anti-IL-
5 receptor-α monoclonal antibody might be useful in the subgroup of COPD patients with sputum 
eosinophilia. 
 
The overlap between asthma and COPD has now been formally recognized to be a separate 
COPD phenotype [7, 8], as sputum eosinophilia can occur in patients with stable COPD despite 
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this immunological response being typically associated with asthma [5].  Mean systemic IL-5 levels 
up to 80 pg/mL have been measured by ELISA in individuals with childhood persistent asthma, 
although much lower levels are generally reported [9].  In a study of stable COPD patients with 
bronchial asthma excluded by a pulmonologist, the eosinophilic chemotactic protein, serum 
eotaxin, was  found to be higher when compared with controls, but this study did not report 
corresponding serum IL-5 values. When compared with smokers with no or minimal lung disease 
as defined by FEV1/FVC > 0.7, FEV1 ≥ 80% and low attenuation areas (LAA) ≤ 2.4, plasma IL-5 
levels were statistically higher for those with radiological evidence of emphysema (LAA ≥ 8), airflow 
obstruction (FEV1/FVC > 0.7, FEV1 ≤ 60%) or both.  While a history of childhood asthma is often 
inaccurate when it is recalled in adulthood, this prospective history is generally unavailable in the 
clinical setting.  As our study participants did not self-report a history of lifetime asthma, it is 
therefore still possible that those with severe COPD may have had end-stage, insidious, allergic 
asthma that was otherwise not detectable.   
 
Elevated serum cytokine levels might be due to a “spill-over” effect of the pathological process in 
the lung into the systemic circulation [10], and a linear and predictable nature cannot be presumed. 
In a key study of eleven subjects with COPD of moderate severity of whom four underwent a 
peripheral blood study, increased numbers of Tc2-like cytokine-expressing cells were isolated from 
BAL fluid, and this was consistent with other data supporting increased IL-4 and IL-13 expression 
by pulmonary Tc2 lymphocytes  [3].  In comparison with the increased numbers of (CD8+) Tc1-like 
cells detectable in blood, only around one-sixth of (CD8+) Tc2-like, (CD4+) TH1-like, and (CD4+) 
TH2-like cells were detectable in the blood compared with BAL fluid.  This suggests that expression 
of IL-5 by pulmonary Tc2 lymphocytes is likely to have been increased, especially for some of our 
participants who had severe COPD. 
  
Our correlation data suggests moderate interrelationships between serum IL-17A levels and the 
cytokine IL-12p70, a promoter of TH1 differentiation, and the cytokine IL-13 that is inhibitory to TH1 
cells.  These represent cytokines from the three different subsets of effector CD4+ T cells, in 
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addition to T-regulatory cells.  The interrelationships are consistent with naïve precursor TH17 cells 
being inhibited by TH1 and TH2 cytokines, although the interpretation of our finding was limited 
without IFN-γ and IL-4 levels.   
  
Over-expression of IL-13 in the lungs of adult mice has been shown to induce many features 
associated with COPD.  These include emphysema, mucus goblet cell hyperplasia, and airway 
inflammation associated with macrophages, lymphocytes and eosinophils and increased matrix 
metalloproteinases.  Low or undetectable levels of tissue IL-13 have been reported in lung 
specimens of human subjects with severe emphysema, whereas plasma levels of IL-13 have been 
shown to be modestly elevated in phenotypes associated with emphysema in another clinical 
study, with and without airflow obstruction.   
  
In terms of limitations, we acknowledge our study had modest numbers of participants (n=35), 
although numbers were comparable to the similar study by Bade and colleagues (n=30).  As the 
measurement of cytokines in the systemic compartment lacks sensitivity when compared with 
either BAL fluid or surgical lung biopsy, this might have attenuated or effectively eliminated 
associations between serum cytokines and the severity categories of COPD.  Other tests that 
would have been useful to be included, including the measurement of IFN-γ, IL-8 and IL-4 for the 
interpretation of serum IL-17A and its relationship to TH1 and TH2 lymphocytic pathways; and 
objective measures of allergic and asthma such as blood eosinophil count, bronchial provocation 
and/or skin prick testing.  Further studies are needed to clarify whether serum IL-5 might be a 
biomarker for severe COPD. 
 
This study aimed to document the systemic immune responses in participants with COPD of 
varying severity, and appears to show an enhanced systemic TH2 expression of IL-5 levels for 
participants who had severe airflow obstruction and a lower mean gas transfer factor. Although the 
cohort of COPD patients is very small these findings support the concept that although the immune 
 8 
mechanisms of COPD and asthma are classically different, increasing disease severity and clinical 
overlap of these two obstructive lung diseases can blur the distinction.   
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Table 1  Baseline spirometry and smoking characteristics 
___________________________________________________________________________ 
Subjects, n = 35    Severe  Mild-  Controls  
      COPD  moderate    
        COPD     
___________________________________________________________________________ 
Subjects, n     8  11  16   
Age (years) ٭     68.6 (13) 72.5 (9.8) 59.2 (12)  
Male: female     4 : 4  9 : 2  5 : 11   
FEV1 post-BD (% predicted) §  36.6 (8.0) 69.8 (13) 109 (15)  
FVC post-BD (% predicted)   80.9 (9.9) 104 (10) 111 (14)  
FEV1/FVC post-BD (ratio) §   30.9 (4.9) 50.7(11) 78.3 (5.9) 
Smoking history (pack-years) †  36.6 (28) 50.3 (24) 17.9 (0-65) a    
Ex/ Current/ Non-smoker, n    7 / 0 / 1 8 / 3 / 0 7 / 3 / 6 
TLCO (% predicted)     40.4 (17) 55.8 (20) --   
___________________________________________________________________________ 
Abbreviations: BD, bronchodilator; FEV1, forced expiratory volume in one second; FVC, forced 
vital capacity; TLCO, transfer factor of the lung for carbon monoxide  
Results are expressed as mean (SD) except where otherwise indicated 





Figure 1 (A) Serum cytokine levels between control and COPD groups. Only serum IL-5 levels 
showed statistical significance between severe COPD and controls (p = 0.005) and between 
severe COPD to mild-moderate COPD (p = 0.005). There was no statistical significance for all 
other serum cytokines,  IL-13 (p = 0.079), G-CSF (p = 0.47), IL-12p70 ((p = 0.41), IL-17A (p = 
0.815), CCL2 (p = 0.18), IL-1β (p = 0.345), IL-7 (p = 0.063) and CCL4 (p = 0.89). (B, C) 
Relationships between serum IL-17A, IL-13 and IL-12p70 levels using log scale graphs. 
 
 
 
 
 
 
 
